The new production site offers ultramodern manufacturing technologies and controlled assembly areas. It also features dedicated cleanrooms certified to ISO 5 and ISO 7 standards equipped with HEPA filters and strict environmental monitoring.
VVT’s facility also houses machine and equipment design areas and a segregated inspection area for raw materials and lot release testing. The expansion strategy also earmarks additional space for custom-built cleanrooms.
The facility will manufacture the ScleroSafe catheter, a coaxial, monorail, double-lumen proprietary catheter. The company currently manufactures it in the U.S. but seeks to identify additional manufacturing capabilities to facilitate growth. This could also decrease manufacturing costs and improve gross margins.
“At VVT Medical, we’re dedicated to transforming lives. We’re working around the clock to scale up and fulfill our mission of reaching as many patients as possible with our non-thermal, anesthesia-free, and painless treatments to eliminate varicose veins,” said CEO Erez Tetro .
The company, in November 2023, announced its first commercial ScleroSafe case in the U.S.
